RecruitingNCT07485140

Prevention of Preeclampsia in Denmark: A National Implementation Study

Prevention of Preeclampsia in Denmark (PREPRED): A National Implementation Study


Sponsor

Copenhagen University Hospital at Herlev

Enrollment

80,000 participants

Start Date

Sep 15, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this clinical study is to learn if a new first-trimester screening program can better find pregnant women who are at high risk of developing preeclampsia and help prevent the condition with early treatment. Preeclampsia is a pregnancy condition that causes high blood pressure and can affect the mother's organs and the baby's growth. Early detection allows doctors to offer preventive treatment, such as low-dose aspirin, which may lower the risk of serious illness. The study includes pregnant women with a single pregnancy who attend their routine first-trimester scan at maternity hospitals in Denmark. The main questions it aims to answer are: Does the new screening program lower the number of women who develop preterm preeclampsia (preeclampsia before thirty-seven weeks of pregnancy)? Can the screening program be carried out safely and be acceptable for pregnant women and healthcare professionals? Researchers will gradually introduce the new screening program across hospitals and compare outcomes before and after the program starts. Women who are found to have a high risk of preeclampsia will be offered preventive treatment with low-dose aspirin. Participants will: Receive information about preeclampsia and the screening during their first-trimester visit Have their blood pressure measured and an ultrasound assessment of blood flow to the uterus during the routine scan Have routine blood samples analysed to estimate their personal risk of preeclampsia Be offered daily low-dose aspirin until late pregnancy if they are identified as high risk Continue standard pregnancy care while researchers follow pregnancy outcomes using national health records The study will help researchers understand whether this screening approach works in everyday care and whether it should become part of routine pregnancy care in Denmark.


Eligibility

Sex: FEMALE

Inclusion Criteria3

  • Pregnant women with a viable singleton pregnancy
  • Attendance at a routine first-trimester ultrasound scan at 11+0 to 13+6 weeks of gestation at a Danish maternity hospital during the study period
  • Valid Danish personal identification number (CPR number) enabling linkage with national health registries

Exclusion Criteria3

  • Multiple pregnancy (e.g., twins or higher-order gestations)
  • Major fetal anomaly diagnosed before completion of first-trimester screening
  • Miscarriage or pregnancy loss diagnosed before completion of first-trimester screening

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERFirst trimester screening for preeclampsia

Screening for preeclampsia using maternal factors, Mean arterial pressure, flow in the uterine arteries and Placental Growth Factor


Locations(3)

Aarhus University

Aarhus, Denmark

University of Copenhagen

Copenhagen, Denmark

University of Copenhagen

Hillerød, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07485140


Related Trials